What can large simple trials do for psychiatry?

American Journal of Psychiatry

Volumn 168, Issue 2, 2011, Pages 117-119

  Scott Stroup, T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; ZIPRASIDONE;

CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT INTERVAL; RISK ASSESSMENT; SCHIZOPHRENIA; SUDDEN DEATH; TORSADE DES POINTES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; DEATH, SUDDEN, CARDIAC; HUMANS; LONG QT SYNDROME; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; THIAZOLES;

EID: 79952719826     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10111652     Document Type: Editorial

References (13)

1. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM: Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2010; 168:193-201
2. Geddes JR: Large simple trials in psychiatry: providing reliable answers to important clinical questions. Epidemiol Psichiatr Soc 2005; 14:122-126
3. Peto R, Baigent C: Trials: the next 50 years: large scale randomised evidence of moderate benefits. BMJ 1998; 317:1170-1171
4. US Food and Drug Administration: NDA 20-825: Approval Letter and Labeling, Feb 5, 2001. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/ 2001/20825ltr.pdf
5. Ray WA, Chung CP, Murray KT, Hall K, Stein CM: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225-235
6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
7. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611-622 (Pubitemid 44464570)
8. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S: Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009; 4:CD006627
9. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152-163
10. US Food and Drug Administration: FDA's Sentinel Initiative. http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm
11. US Food and Drug Administration: The Sentinel Initiative: an update on FDA's progress in building an electronic system for monitoring the postmarket safety of FDA-approved drugs and other products. July 2010. http://www.fda.gov/ downloads/Safety/FDAsSentinelInitiative/UCM233360.pdf
12. Stroup TS, Alves WM, Hamer RM, Lieberman JA: Clinical trials for antipsychotic drugs: design conventions, dilemmas, and innovations. Nat Rev Drug Discov 2006; 5:133-146
13. BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E: Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385-395